Allergy Therapeutics - Vesting of Options under Long-Term Incentive Plan
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Vesting of Options under Long-Term Incentive Plan
The LTIP issued share options to key members of Allergy Therapeutics' management team including certain of its persons discharging managerial responsibilities ("PDMRs"), to encourage long-term value creation and to incentivise those individuals in a manner that aligns with the interests of the Company's stakeholders. The Remuneration Committee set performance conditions across a three-year performance period commencing
Performance Outcome
The Remuneration Committee has reviewed and assessed performance against the conditions attached to the LTIP awards over the performance period. The share price threshold having been met, the regulatory performance targets (representing 30 per cent. of each award) have been achieved and accordingly 30 per cent. of each award has vested. The EBITDA performance targets (representing 70 per cent. of each award) have not been achieved and accordingly 70 per cent. of each award has lapsed.
Under this award, a total of 7,671,078 share options have vested with an exercise price of
|
Name |
Title |
Options vested and exercisable |
Lapsed options |
Resultant number of share options held |
Number of ordinary shares held |
|
|
Chief Executive Officer |
2,895,198 |
6,755,465 |
135,822,559 |
5,001,200 |
|
|
Chief Financial Officer |
1,142,856 |
2,666,668 |
21,338,056 |
1,507 |
|
Total |
|
4,038,054 |
9,422,133 |
|
|
The exercise price of the vested options is
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0)1903 845 820
Cavendish Capital Markets Limited (Nominated Adviser and Broker)
+44 (0)20 7220 0500
ICR Healthcare
+44 (0)20 3709 5700
allergytherapeutics@icrhealthcare.com
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company, headquartered in the
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them in accordance with the
|
1 |
Details of the person discharging managerial responsibilities / persons closely associated |
|
|
a) |
Name |
|
|
2 |
Reason for the notification |
|
|
a) |
Position / status |
Chief Executive Officer |
|
b) |
Initial notification / Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Allergy Therapeutics plc |
|
b) |
LEI |
213800PQ7AHK7KGVOE23 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument |
Ordinary shares of |
|
Identification code |
ISIN: GB00B02LCQ05 |
|
|
b) |
Nature of the transaction |
Vesting of options under the Long-Term Incentive Plan |
|
c) |
Price(s) and volume(s) |
Exercise price per share:
Volume: 2,895,199 |
|
d) |
Aggregated information - Aggregated volume - Price |
See 4c) above |
|
e) |
Date of the transaction |
|
|
f) |
Place of the transaction |
Outside a trading venue |
|
1 |
Details of the person discharging managerial responsibilities / persons closely associated |
|
|
a) |
Name |
|
|
2 |
Reason for the notification |
|
|
a) |
Position / status |
Chief Financial Officer |
|
b) |
Initial notification / Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Allergy Therapeutics plc |
|
b) |
LEI |
213800PQ7AHK7KGVOE23 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument |
Ordinary shares of |
|
Identification code |
ISIN: GB00B02LCQ05 |
|
|
b) |
Nature of the transaction |
Vesting of options under the Long-Term Incentive Plan |
|
c) |
Price(s) and volume(s) |
Exercise price per share:
Volume: 1,142,857 |
|
d) |
Aggregated information - Aggregated volume - Price |
See 4c) above |
|
e) |
Date of the transaction |
|
|
f) |
Place of the transaction |
Outside a trading venue |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE